{"id":45610,"date":"2022-06-28T20:01:26","date_gmt":"2022-06-28T18:01:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\/"},"modified":"2022-06-28T20:01:26","modified_gmt":"2022-06-28T18:01:26","slug":"4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\/","title":{"rendered":"4D pharma plc (\u201c4D pharma\u201d) Receives Notice of Delisting From Nasdaq"},"content":{"rendered":"
\n

LEEDS, England–(BUSINESS WIRE)–4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that on June 27, 2022, it received written notice from The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) stating that in accordance with Listing Rules 5101, 5110(b), and IM-5101-1, Nasdaq Staff (the \u201cStaff\u201d) has determined that 4D pharma\u2019s securities will be delisted from The Nasdaq Stock Market. Accordingly, trading of 4D pharma\u2019s LBPS will be suspended at the opening of business on July 7, 2022, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove 4D pharma\u2019s securities from listing and registration on The Nasdaq Stock Market.\n<\/p>\n

\nThe Staff\u2019s determination was based on the following factors: the associated public interest concerns raised by 4D pharma\u2019s press release dated June 24, 2022 in which 4D pharma announced that it had been placed into administration under English law; and concerns regarding the residual equity interest of the existing holders of listed securities.\n<\/p>\n

\n4D pharma may appeal the Staff\u2019s determination to the Hearing Panel, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.\n<\/p>\n

\nAbout 4D pharma<\/strong>\n<\/p>\n

\n4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D pharma has developed a proprietary platform, MicroRx\u00ae, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.\n<\/p>\n

\n4D pharma\u2019s Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D pharma has six clinical programs, namely a Phase I\/II study of MRx0518 in combination with KEYTRUDA\u00ae (pembrolizumab) in solid tumors, a Phase II clinical trial of MRx0518 in combination with BAVENCIO\u00ae (avelumab) in the first-line maintenance setting for urothelial carcinoma, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I\/II study of MRx-4DP0004 in asthma, and Blautix\u00ae in irritable bowel syndrome (IBS) which has completed a successful Phase II trial. Additional preclinical-stage programs include candidates for CNS disease, immune-inflammatory conditions and cancer. 4D pharma has a research collaboration with MSD (a tradename of Merck & Co., Inc., Kenilworth, NJ, USA), to discover and develop Live Biotherapeutics for vaccines.\n<\/p>\n

\nFor more information, refer to https:\/\/www.4dpharmaplc.com<\/a>.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis announcement contains \u201cforward-looking statements.\u201d All statements other than statements of historical fact contained in this announcement, including without limitation statements regarding the timing of studies, are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), and Section 21E of the United States Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d). Forward-looking statements are often identified by the words \u201cbelieve,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201cintend,\u201d \u201cforesee,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cmay,\u201d \u201cestimate,\u201d \u201coutlook\u201d and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on 4D pharma\u2019s current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on 4D pharma. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting 4D pharma will be those that it anticipates.\n<\/p>\n

\nAll of 4D pharma\u2019s forward-looking statements involve known and unknown risks and uncertainties, some of which are significant or beyond its control, and assumptions that could cause actual results to differ materially from 4D pharma\u2019s historical experience and its present expectations or projections. The foregoing factors and the other risks and uncertainties that could cause actual results to differ materially include potential delays in the process of delisting and, if pursued by 4D pharma, the outcome of any appeal of the Staff\u2019s determination. 4D pharma wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. 4D pharma undertakes no obligation to publicly update or revise any of its forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\n4D pharma<\/b>
Investor Relations ir@4dpharmaplc.com<\/a>\n<\/p>\n

\nSinger Capital Markets – Nominated Adviser and Joint Broker<\/b>
Philip Davies \/ James Fischer (Corporate Finance) +44 (0)20 7496 3000
\n
Tom Salvesen (Corporate Broking)\n<\/p>\n

\nBryan Garnier & Co. Limited – Joint Broker<\/b>
Dominic Wilson +44 (0)20 7332 2500\n<\/p>\n

\nStern Investor Relations<\/b>
Julie Seidel +1-212-362-1200
\n
julie.seidel@sternir.com<\/a>\n<\/p>\n

\nImage Box Communications<\/b>
Neil Hunter \/ Michelle Boxall +44 (0)20 8943 4685
\n
neil@ibcomms.agency<\/a> \/ michelle@ibcomms.agency<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LEEDS, England–(BUSINESS WIRE)–4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that on June 27, 2022, it received written notice from The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) stating that in accordance with Listing Rules 5101, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45610","6":"format-standard","7":"category-industry"},"yoast_head":"\n4D pharma plc (\u201c4D pharma\u201d) Receives Notice of Delisting From Nasdaq - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"4D pharma plc (\u201c4D pharma\u201d) Receives Notice of Delisting From Nasdaq - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LEEDS, England–(BUSINESS WIRE)–4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that on June 27, 2022, it received written notice from The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) stating that in accordance with Listing Rules 5101, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-28T18:01:26+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"4D pharma plc (\u201c4D pharma\u201d) Receives Notice of Delisting From Nasdaq\",\"datePublished\":\"2022-06-28T18:01:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\\\/\"},\"wordCount\":821,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\\\/\",\"name\":\"4D pharma plc (\u201c4D pharma\u201d) Receives Notice of Delisting From Nasdaq - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-06-28T18:01:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"4D pharma plc (\u201c4D pharma\u201d) Receives Notice of Delisting From Nasdaq\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"4D pharma plc (\u201c4D pharma\u201d) Receives Notice of Delisting From Nasdaq - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\/","og_locale":"en_US","og_type":"article","og_title":"4D pharma plc (\u201c4D pharma\u201d) Receives Notice of Delisting From Nasdaq - Pharma Trend","og_description":"LEEDS, England–(BUSINESS WIRE)–4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that on June 27, 2022, it received written notice from The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) stating that in accordance with Listing Rules 5101, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-28T18:01:26+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"4D pharma plc (\u201c4D pharma\u201d) Receives Notice of Delisting From Nasdaq","datePublished":"2022-06-28T18:01:26+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\/"},"wordCount":821,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\/","url":"https:\/\/pharma-trend.com\/en\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\/","name":"4D pharma plc (\u201c4D pharma\u201d) Receives Notice of Delisting From Nasdaq - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-06-28T18:01:26+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/4d-pharma-plc-4d-pharma-receives-notice-of-delisting-from-nasdaq\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"4D pharma plc (\u201c4D pharma\u201d) Receives Notice of Delisting From Nasdaq"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45610"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45610\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45610"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45610"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}